4-aminopyridyl-based lead compounds targeting CYP51 prevent spontaneous parasite relapse in a chronic model and improve cardiac pathology in an acute model of Trypanosoma cruzi infection.

• Main Authors: Claudia Magalhaes Calvet (Author), Jun Yong Choi (Author), Diane Thomas (Author), Brian Suzuki (Author), Ken Hirata (Author), Sharon Lostracco-Johnson (Author), Liliane Batista de Mesquita (Author), Alanderson Nogueira (Author), Marcelo Meuser-Batista (Author), Tatiana Araujo Silva (Author), Jair Lage Siqueira-Neto (Author), William R Roush (Author), Mirian Claudia de Souza Pereira (Author), James H McKerrow (Author), Larissa M Podust (Author)
• Format: Book
• Published: Public Library of Science (PLoS), 2017-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Chagas disease, caused by the protozoan Trypanosoma cruzi, is the leading cause of heart failure in Latin America. The clinical treatment of Chagas disease is limited to two 60 year-old drugs, nifurtimox and benznidazole, that have variable efficacy against different strains of the parasite and may...